<DOC>
	<DOCNO>NCT01586000</DOCNO>
	<brief_summary>This clinical trial experimental research study use potential new form birth control . Clinical trial include people volunteer take part study . Take time decide want part experimental research study . If want know study first , ask study doctor study site staff . The investigator also give study information write doctor clinic staff .</brief_summary>
	<brief_title>A Dose-finding Study Evaluate Effect Contraceptive Vaginal Ring , Releasing Nestorone® Estradiol , Cycle Control , Ovulation Inhibition , Pharmacokinetics Normal Cycling Women</brief_title>
	<detailed_description />
	<mesh_term>ST 1435</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Women meet follow criterion eligible enrollment trial : 1 . Healthy woman reproductive age ( 1839 year , inclusive , enrollment visit ) . 2 . Have regular menstrual cycle 2135 day duration . 3 . Have intact uterus ovary . 4 . Will able willing comply protocol sign inform consent . 5 . Will risk pregnancy . They consistently use nonhormonal method , surgically sterile male partner vasectomy , abstinent , samesex relationship control period study exit ( include recovery period ) . 6 . Will diastolic blood pressure ( BP ) ≤85 mm Hg systolic BP ≤135 mm Hg 5 minute sit position . 7 . Willing abstain use nonwater base vaginal lubricant study . Women meet follow criterion eligible enrollment trial : 1 . Participating another clinical trial involve investigational product within last 30 day ( prior screening ) planning participate another clinical trial study . 2 . Not live catchment area clinic . 3 . Known hypersensitivity progestins estrogen . 4 . All contraindication combine estrogenprogestin contraceptive use include : Thrombophlebitis thromboembolic disorder . Past personal history deep vein thrombophlebitis thromboembolic disorder . History venous thrombosis embolism firstdegree relative &lt; 55 year age suggest familial defect blood coagulation system , opinion investigator , suggest use hormonal contraceptive could pose significant risk . History stroke . Known suspected carcinoma breast . Carcinoma endometrium know suspected estrogendependent neoplasia . Undiagnosed abnormal genital bleeding . Cholestatic jaundice pregnancy jaundice prior oral contraceptive use . Hepatic adenoma carcinoma . Known suspected pregnancy . Smoking woman 35 year 35 year course trial ; woman &lt; 35 year smoke 15 cigarette per day must evaluate investigator inclusion base risk factor would increase risk cardiovascular disease ( CVD ) thromboembolism , e.g . lipid level , glucose level , BP , BMI , family history CVD young age . History retinal vascular lesion , unexplained partial complete loss vision . Headaches focal neurological symptom ( e.g. , migraine aura ) . 5 . Desire become pregnant study . 6 . Breastfeeding . 7 . Undiagnosed vaginal discharge vaginal lesion abnormality . Subjects diagnose screen Chlamydia gonococcus infection may include trial follow treatment ; partner treatment also recommend . Subjects vaginitis ( yeast , trichomonas , bacterial vaginitis ) may enrol treatment . Investigators make determination subject high risk reinfection , e.g . multiple sex partner , untreated partner , whether subject include . In accordance PI/medical designee assessment local standard practice , woman history genital herpes include outbreaks infrequent . 8 . A clinically significant Pap test abnormality , manage current local national guideline . Women current abnormal Pap ( within last nine month ) : In accordance Bethesda system classification : smear suggestive highgrade precancerous lesion ( ) , include high grade squamous intraepithelial lesion ( HGSILs ) , exclude ; Women low grade squamous intraepithelial lesion ( LGSIL ) atypical squamous cell undetermined significance ( ASCUS ) /highrisk human papillomavirus ( HPV ) positive , Atypical squamous cell , rule high grade lesion ( ASCH ) may participate evaluate colposcopy biopsy determine evidence lesion severity great cervical intraepithelial neoplasia ( CIN ) I . Women biopsy find CIN I followup find per standard care ; woman exclude treatment indicate . In accordance Pap class system : Women high grade dysplasia exclude . Women low grade dysplasia CIN I interpretation Pap test may participate follow exclusion high grade lesion colposcopic evaluation base Investigator discretion provide appropriate follow accordance local standard . 9 . Known benign malignant liver tumor ; know active liver disease . 10 . Invasive cancer ( past history carcinoma sarcoma , except nonmelanoma skin cancer ) . 11 . Current past medically diagnose severe depression , , opinion investigator , could exacerbate use hormonal contraceptive . 12 . Known suspected current alcoholism drug abuse . 13 . Elevated serum fast clinical chemistry value complete blood count ( CBC ) value designate clinically significant investigator medically qualify subinvestigator . 14 . Uncontrolled thyroid disease . 15 . Known impaired hypothalamicpituitaryadrenal reserve . 16 . Body mass index ( BMI ) &gt; 35 . 17 . Use injectable contraceptive ( e.g . cyclofem depomedroxyprogesterone acetate ) 6 month prior enrollment spontaneous menses since last injection . 18 . Use oral contraceptive within one month prior start control cycle ( subject must undergo informed consent process screening procedure stop oral contraceptive participate study ) . 19 . Use hormonal contraceptive . NOTE : Removal implant hormonal contraceptive must personal reason unrelated purpose enrollment study . 20 . Current use intrauterine device ( IUD ) . NOTE : Removal IUD must personal reason unrelated purpose enrollment study . 21 . Known hypersensitivity silicone rubber . 22 . History toxic shock syndrome . 23 . Cystoceles rectoceles anatomical abnormality would preclude use vaginal ring . 24 . Planning undergo major surgery study . 25 . Severe constipation . 26 . Use liver enzyme inducer inhibitor regular basis . 27 . Known HIV infection . 28 . Bariatric surgery within past year prior enrollment . 29 . Any abnormality find transvaginal ultrasound ( TVUS ) PI medically qualify subinvestigator deems put subject risk . 30 . Have issue concern ( judgment investigator ) may compromise safety subject confound reliability compliance information acquire study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>vaginal ring</keyword>
</DOC>